Guideline Summary: Empiric Antibiotic Management for Hirschsprung‑Associated Enterocolitis

Risk Assessment and Clinical Instability

Children with Hirschsprung disease who develop gastrointestinal symptoms accompanied by systemic signs (e.g., fever, tachycardia, altered perfusion) should be regarded as clinically unstable and managed urgently. 1

First‑line empiric therapy should consist of an antipseudomonal β‑lactam (e.g., piperacillin‑tazobactam or cefepime) or a carbapenem (e.g., meropenem or imipenem). [2][1]
The regimen must provide coverage for Gram‑negative organisms (including Pseudomonas aeruginosa), Gram‑positive organisms, and anaerobes because the source is colonic. [2][3]
In clinically unstable patients or when resistant pathogens are suspected, add a second Gram‑negative agent or a glycopeptide (vancomycin). [2][1]

Antimicrobial dosing should be individualized using pharmacokinetic/pharmacodynamic principles, taking into account the child’s age, weight, and renal function. 1

Obtain blood cultures without causing a substantial delay in antibiotic administration; start antibiotics immediately after cultures are drawn. 1
In septic shock or severe sepsis‑associated organ dysfunction, initiate antimicrobial therapy within 1 hour of recognition. 1
Even in the absence of overt shock, children with suspected Hirschsprung‑associated enterocolitis should receive antibiotics as soon as possible after appropriate evaluation. 1

Provide aggressive fluid resuscitation with isotonic intravenous fluids (e.g., lactated Ringer’s or normal saline) for any signs of dehydration or shock. 5

Narrow antimicrobial therapy based on culture results and susceptibility testing; this recommendation is strong and supported by high‑quality evidence. [5][1]
Discontinue double Gram‑negative coverage or empiric vancomycin after 24–72 hours if there is no microbiologic indication for continued combination therapy. 3
Perform daily assessments for de‑escalation, guided by clinical improvement and laboratory data. 1

Determine the length of antimicrobial treatment according to the severity of enterocolitis, identified pathogen, and the patient’s clinical response. 1
Do not alter antibiotics solely because fever persists if the child is otherwise clinically stable; decisions should be based on overall clinical and microbiologic assessment. 3

Avoid the use of antimotility agents (e.g., loperamide) in suspected enterocolitis, as they can worsen obstruction and increase perforation risk. 5
Recognize that while empiric antibiotics are generally not indicated for uncomplicated acute watery diarrhea in otherwise healthy children, the presence of Hirschsprung disease markedly lowers the threshold for early antimicrobial therapy. 5